https://www.selleckchem.com/pr....oducts/ipilimumab.ht
12% of patients were classified as being in the low-risk category and could safely forgo adjuvant chemotherapy. For every unit increase in the EPclin Risk Score, the percentage increase in absolute chemotherapy benefit was 6.82%. Similarly, the correlation between the likelihood of recurrence within 5 to 15 years and the EPclin Risk Score suggested that there is a 10.34% increase in recurrence for each unit of EPclin Risk Score. The EPclin Risk Score has good prognostic and predictive power; it also provides the range of chemotherapy
Like
Comment
Share
